Abstract
Evaluation of: Mitchell MS, Abrams J, Thompson JA et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon-α2b compared with high-dose interferon-α2b for resected stage III cutaneous melanoma. J. Clin. Oncol. 20, 2078–2085 (2007).Malignant melanoma remains the most lethal form of cancer, especially for those with lymph node involvement or metastases. Owing to its intrinsic nature of highly resistance to conventional chemotherapy and radiotherapy, advanced melanoma was considered by most to be indolent, defying any tempts to cure. For decades, there had been studies on the adjuvant treatment in order to lower recurrence rate and to improve the likelihood of response. Clinical trials are currently ongoing to explore the role of specific active immunotherapy (vaccine) in the treatment of patients with high risk of recurrence and metastasis. The current paper under evaluation described one randomized Phase III trial of the therapeutic vaccine Melacine® plus low-dose IFN-α2b, which had an effect comparable to standard high-dose interferon-α2b but with less toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
